Decision on the introduction of incentive programs for employees and consultants
The meeting resolved that the program shall consist of a maximum of 72,500 warrants, each of which entitles the holder to subscribe for one share in the Company.
Decision on the introduction of an incentive program for board members
The meeting resolved that the program shall consist of a total of a maximum of 52,500 warrants, each of which entitles the holder to subscribe for one share in the Company.
All resolutions at the extra general meeting were resolved unanimously. Minutes (in Swedish) are available on Lipum's website.
For further information, please contact:
Einar Pontén, CEO
Mobile: +46 70 578 34 95
The Board of Directors
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: email@example.com, phone: +46 8 503 000 50.